Longevity
Qihan scores FDA ‘triple crown’ for cell therapy
Chinese biotech’s universal CAR-T therapy secures FDA’s three top expedited designations, potentially accelerating its path to patients. Qihan Biotech has reached a landmark moment in its journey to bring next-generation cell therapies to patients. The Hangzhou-based company has announced that its lead candidate, QT-019B, has received both Regenerative Medicine Advanced Therapy (RMAT) designation and Breakthrough […] The post Qihan scores FDA ‘triple crown’ for cell therapy appeared first on Longevity.Technology .
This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.
Read full coverage at Longevity.Technology →